Curis Inc., a biotechnology company specializing in the development of emavusertib, has announced a significant financial move involving a registered direct offering and a concurrent private placement. The company has entered into an agreement with both existing and new investors to purchase 1,538,460 shares of its common stock. Additionally, Curis will issue unregistered pre-funded warrants to acquire up to 1,538,461 shares of common stock at a nominal exercise price and unregistered warrants to purchase up to 3,076,921 shares at an exercise price of $2.15 per share. The private placement is set at a combined purchase price of $2.275 for one share and the associated warrant, and $2.265 for one pre-funded warrant and the associated warrant. This strategic financial arrangement aims to bolster Curis's capital as it continues to focus on the advancement of its IRAK4 inhibitor, emavusertib.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.